Biomarker Analysis of Solid Cancers Such as Gastrointestinal Cancer

Recruiting

• Conditions: Sarcoma

• Registration Number: NCT01831609
• Lead Sponsor: Samsung Medical Center

Brief Summary

To prospectively collect ascites, pleural fluid, circulating tumor cells and derived primary cultures from metastatic cancer patients. The specimens will be analyzed using DNA/RNA/proteomic approaches.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-08-31
• Study First Submitted: 2013-04-07
• Study First Submitted QC: 2013-04-12
• Study First Posted: 2013-04-15
• Status Verified: 2022-06
• Last Update Submitted: 2022-06-13
• Last Update Posted: 2022-06-15
• Primary Completion: 2023-12
• Study Completion: 2024-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

1. Patients with histologically confirmed gastrointestinal, genitourinary, sarcoma, rare cancer
2. Written informed consent
3. body fluid derived from cancer, available for drainage and collection

Exclusion Criteria

• patients who do not give informed consent form for research use of biomaterials/biospecimens

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Biomarker analyses to predict treatment response in metastatic cancer	3 year	Using patient derived tumor cells, predictive biomarker analyses (DNA, RNA protein levels etc) will be assessed.

Trial Locations

Locations (1)

Samsung Medical Center; 🇰🇷 Seoul, Korea, Republic of